Dosage and administration
Apply every morning to face, neck, décolletage and hands. Reapply as needed. For optimal results, use daily with Neova [DNA + Copper] products.
Apply every morning to face, neck, décolletage and hands. Reapply as needed. For optimal results, use daily with Neova [DNA + Copper] products.
Apply every morning to face, neck, décolletage
and hands. Reapply as needed. For optimal results, use daily
with Neova [DNA + Copper] products.
in a 2.5 fl. oz. / 74 mL tube.
Zinc Oxide 7.5%, Octinoxate 7.5%, Octisalate 2.5%.
Water (Aqua), Isopropyl Palmitate,
Octyl Stearate, Ethyl Hexyl Isononanoate, Cyclopentasiloxane,
Cetearyl Glucoside, Micrococcus Lysate,
Plankton Extract, L-ergothioneine, Dimethicone,
Glycereth-26, Sodium Hyaluronate, Panthenol, Allantoin,
Tocopheryl Acetate, Ascorbyl Palmitate (Vitamin C),
Oleth-3 Phosphate, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl
Taurate Copolymer, Polyisobutene, PEG-7
Trimethylolpropane Coconut Ether, Lecithin, Polyether-1,
Phenoxyethanol, Butylene Glycol, Citric Acid, Iodopropynyl
Butylcarbamate, Triethoxycaprylylsilane.
PkgInsertUniversalpg1.jpg PkgInsertUniversalpg2.jpg AmpuleEday.jpg PouchEday.jpg
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 62362-139-03 | 2019-11-13 | C162847 | 48780-1 | 97449f38-c944-f6ea-e053-dbdaa90aa703 | Neova DNA Damage Control - Everyday SPF 43 - 2mL sample package insert |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 62362-139-02 | Neova DNA Damage Control - EverydaySPF 43 | 2 mL in 1 PACKAGE | EMULSION | 2 | 1 | |
| 62362-139-03 | Neova DNA Damage Control - EverydaySPF 43 | 1 in 1 POUCH | EMULSION | 1 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| Octisalate | ACTIVE INGREDIENT | 4X49Y0596W | 1 | |
| Zinc Oxide | ACTIVE INGREDIENT | SOI2LOH54Z | 1 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| Octisalate | ACTIVE MOIETY | 4X49Y0596W | 1 | |
| Zinc Oxide | ACTIVE MOIETY | SOI2LOH54Z | 1 | |
| Allantoin | INACTIVE INGREDIENT | 344S277G0Z | 1 | |
| Alpha-Tocopherol Acetate | INACTIVE INGREDIENT | 9E8X80D2L0 | 1 | |
| Ascorbyl Palmitate | INACTIVE INGREDIENT | QN83US2B0N | 1 | |
| Butylene Glycol | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| Cetearyl Glucoside | INACTIVE INGREDIENT | 09FUA47KNA | 1 | |
| Citric Acid | INACTIVE INGREDIENT | 2968PHW8QP | 1 | |
| Cyclomethicone 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 1 | |
| Dimethicone | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| Egg Phospholipids | INACTIVE INGREDIENT | 1Z74184RGV | 1 | |
| Ergothioneine | INACTIVE INGREDIENT | BDZ3DQM98W | 1 | |
| Ethylhexyl Isononanoate | INACTIVE INGREDIENT | I6KB4GE3K4 | 1 | |
| Glycereth-26 | INACTIVE INGREDIENT | NNE56F2N14 | 1 | |
| Hyaluronate Sodium | INACTIVE INGREDIENT | YSE9PPT4TH | 1 | |
| Iodopropynyl Butylcarbamate | INACTIVE INGREDIENT | 603P14DHEB | 1 | |
| Isopropyl Palmitate | INACTIVE INGREDIENT | 8CRQ2TH63M | 1 | |
| Octyl Stearate | INACTIVE INGREDIENT | 772Y4UFC8B | 1 | |
| Oleth-3 Phosphate | INACTIVE INGREDIENT | 8Q0Z18J1VL | 1 | |
| Panthenol | INACTIVE INGREDIENT | WV9CM0O67Z | 1 | |
| Polyisobutylene (1300 MW) | INACTIVE INGREDIENT | 241BN7J12Y | 1 | |
| Triethoxycaprylylsilane | INACTIVE INGREDIENT | LDC331P08E | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 62362-139 | 62362-139-02, 62362-139-03 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / OPHTHALMIC | 0.03 %w/v | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / TOPICAL | 0.2 mg | ||
| Egg Phospholipids | EGG PHOSPHOLIPIDS | 1Z74184RGV | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 48.75 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRABURSAL | ADJ PH | ||
| Egg Phospholipids | EGG PHOSPHOLIPIDS | 1Z74184RGV | EMULSION / INTRAVENOUS | 1.2 %w/v | ||
| Isopropyl Palmitate | ISOPROPYL PALMITATE | 8CRQ2TH63M | FILM, EXTENDED RELEASE / TRANSDERMAL | 187.5 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / ORAL | 315 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / OPHTHALMIC | ADJ PH | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | NA | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / TOPICAL | 0.01 %w/v | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAMUSCULAR | 0.05 %w/v | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 1 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, COATED / ORAL | NA | ||
| Cyclomethicone 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | CREAM, AUGMENTED / TOPICAL | 260 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / RESPIRATORY (INHALATION) | 8 mg | ||
| Butylene Glycol | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TRANSDERMAL | 8.12 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRA-ARTICULAR | ADJ PH | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET / ORAL | 914 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / EPIDURAL | 0.02 %w/v | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / ORAL | 114 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | DROPS / ORAL | NA | ||
| Ascorbyl Palmitate | ASCORBYL PALMITATE | QN83US2B0N | SYSTEM / TOPICAL | 0.04 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET / SUBLINGUAL | 24 mg | ||
| Hyaluronate Sodium | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAVITREAL | 23 mg | ||
| Alpha-Tocopherol Acetate | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | CAPSULE / ORAL | 2 mg | ||
| Isopropyl Palmitate | ISOPROPYL PALMITATE | 8CRQ2TH63M | OINTMENT / TOPICAL | NA | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| Allantoin | ALLANTOIN | 344S277G0Z | GEL / TOPICAL | 8 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | DOUCHE / VAGINAL | 0.07 %w/w | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRA-ARTICULAR | ADJ PH | ||
| Egg Phospholipids | EGG PHOSPHOLIPIDS | 1Z74184RGV | INJECTION, EMULSION / INTRAVENOUS | 12852 mg | ||
| Cyclomethicone 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INHALANT / RESPIRATORY (INHALATION) | NA | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / TOPICAL | NA | ||
| Isopropyl Palmitate | ISOPROPYL PALMITATE | 8CRQ2TH63M | CREAM / TOPICAL | 112 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / RESPIRATORY (INHALATION) | 0.13 %w/w | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | ELIXIR / ORAL | 100 mg/5ml | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / BUCCAL | NA | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SWAB / TOPICAL | 0.05 %w/w | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / AURICULAR (OTIC) | 0.04 %w/w | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / RECTAL | 7 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CAPSULE, EXTENDED RELEASE / ORAL | 101 mg | ||
| Isopropyl Palmitate | ISOPROPYL PALMITATE | 8CRQ2TH63M | AEROSOL, SPRAY / TOPICAL | 397 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION, CONCENTRATE / INTRAVENOUS | NA | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAMUSCULAR | 28 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EXTENDED RELEASE / ORAL | 45 mg | ||
| Ascorbyl Palmitate | ASCORBYL PALMITATE | QN83US2B0N | SUPPOSITORY / RECTAL | 16 mg | ||
| Ascorbyl Palmitate | ASCORBYL PALMITATE | QN83US2B0N | TABLET / ORAL | 7.14 mg | ||
| Isopropyl Palmitate | ISOPROPYL PALMITATE | 8CRQ2TH63M | GEL / TOPICAL | NA | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / ORAL | 269 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 608 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TROCHE / ORAL | 12 mg | ||
| Hyaluronate Sodium | HYALURONATE SODIUM | YSE9PPT4TH | GEL / TOPICAL | 463 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 38 mg | ||
| Citric Acid | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / ORAL | 446 mg | ||
| Alpha-Tocopherol Acetate | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | FILM / BUCCAL | 0.09 mg | ||
| Isopropyl Palmitate | ISOPROPYL PALMITATE | 8CRQ2TH63M | FILM / TRANSDERMAL | 2 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a4c08463-942b-4f1d-a483-1d56aee78d85 | 77a587f5-d532-405b-91d9-2f0b27c24617 | 2012-01-06 | a4c08463-942b-4f1d-a483-1d56aee78d85 77a587f5-d532-405b-91d9-2f0b27c24617 |
Adverse event summaries are temporarily unavailable. Other product information remains available.